Reshape Lifesciences Inc (STU:24O0)

€ 0.615 0 (0%) Market Cap: 3.67 Mil Enterprise Value: 2.59 Mil PE Ratio: 0 PB Ratio: 1.07 GF Score: 38/100

Q1 2024 ReShape Lifesciences Inc Earnings Call Transcript
May 15, 2024

Earnings
Q4 2023 ReShape Lifesciences Inc Earnings Call Transcript
Apr 01, 2024

Earnings
Q3 2023 ReShape Lifesciences Inc Earnings Call Transcript
Nov 08, 2023

€0.615

Earnings
Q2 2023 ReShape Lifesciences Inc Earnings Call Transcript
Aug 07, 2023

€1.22 (-1.61%)

Earnings
ReShape Lifesciences Inc at OTC Markets Life Science Investor Forum Transcript
Jun 22, 2023
Q1 2023 ReShape Lifesciences Inc Earnings Call Transcript
May 15, 2023

€2.06 (-0.96%)

Earnings
Q4 2022 ReShape Lifesciences Inc Earnings Call Transcript
Apr 25, 2023

€2.26 (-3.42%)

Earnings
Q3 2022 ReShape Lifesciences Inc Earnings Call Transcript
Nov 14, 2022

€10.24 (-2.24%)

Earnings
Q2 2022 ReShape Lifesciences Inc Earnings Call Transcript
Aug 15, 2022

€23.93 (+7.87%)

Earnings
Q1 2022 ReShape Lifesciences Inc Earnings Call Transcript
May 23, 2022

€37.14 (-1.93%)

Earnings
Q4 2021 ReShape Lifesciences Inc Earnings Call Transcript
Mar 28, 2022

€62 (+3.77%)

Earnings
ReShape Lifesciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Q4 2019 Obalon Therapeutics Inc Earnings Call Transcript
Feb 27, 2020

Earnings
Q3 2019 Obalon Therapeutics Inc Earnings Call Transcript
Nov 08, 2019

Earnings
Q2 2019 Obalon Therapeutics Inc Earnings Call Transcript
Jul 24, 2019

Earnings
Q4 2018 Obalon Therapeutics Inc Earnings Call Transcript
Feb 22, 2019

Earnings

Q3 2023 ReShape Lifesciences Inc Earnings Call Transcript

Nov 08, 2023 / 10:00PM GMT

Release Date Price: €0.615

Transcript 10-Q8-K

Operator

Good afternoon, and thank you for joining the ReShape Lifesciences third quarter 2023 conference call. I I'd now like to turn the call over to Michael Miller from Rx Communications.

Michael Miller

Rx Communications Group - IR

Good afternoon, and thank you for joining the ReShape Lifesciences third quarter 2023 earnings call. I'm pleased to be joined today by Paul Hickey, President and Chief Executive Officer; and Thomas Stankovich, Chief Financial Officer.

Paul will provide an overview and update on the company's activities, which will include a discussion with Dr. Caroline Apovian, a member of ReShape's Scientific Advisory Board. Then Thom will review the financial results for the period. I'll then turn the call back over to Paul for some closing remarks, after which we'll open the call to a question and answer session.

As a reminder, this conference call as well as ReShape Lifesciences SEC filings and website, including the investor information section of the website contains forward-looking statements within the meaning of the Private

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.